Published in Inflamm Bowel Dis on July 01, 2004
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol (2007) 1.56
Pain and inflammatory bowel disease. Inflamm Bowel Dis (2009) 1.39
Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J Immunol (2010) 1.31
Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol (2005) 1.17
Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis (2010) 1.14
Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig Dis Sci (2010) 0.95
The cardinal role of the phospholipase A(2)/cyclooxygenase-2/prostaglandin E synthase/prostaglandin E(2) (PCPP) axis in inflammostasis. Inflamm Res (2011) 0.93
Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction? World J Gastroenterol (2006) 0.89
Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am J Pathol (2005) 0.87
TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.87
Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. Biomed Res Int (2013) 0.84
Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis. World J Gastroenterol (2011) 0.83
Selective COX-2 inhibition reduces leukocyte sticking and improves the microcirculation in TNBS colitis. Dig Dis Sci (2006) 0.81
Colorectal cancer chemoprevention by mesalazine and its derivatives. J Biomed Biotechnol (2012) 0.80
The functional -765G→C polymorphism of the COX-2 gene may reduce the risk of developing crohn's disease. PLoS One (2010) 0.80
Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis. Curr Ther Res Clin Exp (2008) 0.78
Environmental risk factors for inflammatory bowel diseases: Evidence based literature review. World J Gastroenterol (2016) 0.76
Preventive health measures in inflammatory bowel disease. World J Gastroenterol (2016) 0.75
Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease. Gastroenterol Res Pract (2015) 0.75
Environmental influences on the onset and clinical course of Crohn's disease-part 2: infections and medication use. Gastroenterol Hepatol (N Y) (2013) 0.75
Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation. EMBO Mol Med (2017) 0.75
Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. Pharmaceuticals (Basel) (2015) 0.75
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 19.08
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 5.39
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology (2004) 4.42
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology (2005) 3.41
Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology (2002) 3.21
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol (2003) 2.96
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology (2002) 2.66
Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol (2004) 2.53
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet (2010) 2.51
Biologic therapy of inflammatory bowel disease. Gastroenterology (2002) 2.49
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35
Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol (2004) 2.24
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20
A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet (2003) 2.17
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16
Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol (2006) 2.14
Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol (2006) 2.12
Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol (2008) 2.09
Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol (2006) 2.06
TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology (2008) 2.06
Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol (2004) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93
Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology (2008) 1.89
Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88
TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol (2004) 1.85
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75
Capsule endoscopy in patients with Crohn's disease: diagnostic yield and safety. Gastrointest Endosc (2009) 1.73
IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis (2007) 1.71
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol (2009) 1.66
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62
Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol (2007) 1.61
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun (2010) 1.57
The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol (2007) 1.56
Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis (2007) 1.55
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum (2009) 1.53
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut (2010) 1.53
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet (2012) 1.52
Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol (2004) 1.52
Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol (2005) 1.51
Defects in mucosal immunity leading to Crohn's disease. Immunol Rev (2005) 1.48
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.43
Colorectal cancer screening and surveillance in Crohn's colitis. J Crohns Colitis (2012) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease. Dig Dis Sci (2013) 1.40
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ Health Perspect (2013) 1.33
Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis (2007) 1.33
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol (2008) 1.28
Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease. Inflamm Bowel Dis (2009) 1.27
Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.27
Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis (2010) 1.25
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol (2004) 1.24
TNFSF15 is an ethnic-specific IBD gene. Inflamm Bowel Dis (2007) 1.24
Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep (2008) 1.23
Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology (2008) 1.23
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23